Shilpa Medicare Research Report By FirstCall

Shilpa Medicare Limited was established in 1987. It is engaged in the manufacture and sale of bulk drugs and intermediates in India. It offers oncology products, active pharmaceutical ingredients, fine chemicals, herbal products, and specialty chemical products. The company also exports its products to the United States, Canada, Australia, and Japan; European countries, such as Germany, Switzerland, the Netherlands, Belgium, Spain, Greece, Cyprus, Italy, the United Kingdom, etc.; South American countries, including Mexico, Brazil, Columbia, etc.; African countries comprising Kenya, Nigeria, West Indies, etc.; and Asian countries consisting of Singapore, Taiwan, China, Malaysia, and Thailand.

We expect that the company surplus scenario is likely to continue for the next three years, will keep its growth story in the coming quarters also. We recommend ‘BUY’ in this particular scrip with a target price of Rs. 577.00 for Medium to Long term investment.

Download Shilpa Medicare Firstcall Report